WealthShield Partners’s Starling Oncology STLN Stock Holding History

WealthShield Partners’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-70,154	Closed	-$215K	–	589
2026 Q1	$215K	Hold	70,154	–	–	0.02%	332
2025 Q4	$250K	Hold	70,154	–	–	0.03%	307
2025 Q3	$245K	Hold	70,154	–	–	0.03%	302
2025 Q2	$144K	Hold	70,154	–	–	0.02%	349
2025 Q1	$80K	Buy	+70,154	New	+$54.3K	0.01%	391
2024 Q2	–	Sell	-24,126	Closed	-$38.1K	–	489
2024 Q1	$38.1K	Hold	24,126	–	–	0.01%	356
2023 Q4	$49.2K	Buy	+24,126	New	+$41.8K	0.01%	361

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

WealthShield Partners's STLN Position: Q2 2026 in Review

WealthShield Partners sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 70,154 shares — an estimated $215K sold.

WealthShield Partners first reported a position in STLN in Q4 2023 and held it in 7 quarters. The position peaked at $250K in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

WealthShield Partners reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
WealthShield Partners sold 70,154 Starling Oncology shares in Q2 2026, an estimated $215K.
WealthShield Partners first reported a position in Starling Oncology in Q4 2023 and held it in 7 quarters.
WealthShield Partners's Starling Oncology position peaked at $250K in Q4 2025.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on WealthShield Partners's 13F filing for Q2 2026, filed 12 Aug 2026.